UBM India Flags-off CPhI/P-MEC India 2014

MUMBAI, December 2, 2014 /PRNewswire/ --

- Launches CPhI Pharma Insights: India 2015 Report

- Announces Winners of India Pharma Awards

UBM India today flagged off Asia's biggest pharma show, the CPhI/P-MEC India 2014, at the Goregaon Exhibition Center, Mumbai. Along with its co-located events P-MEC and ICSE, CPhI/P-MEC India serves as a platform wherein key players of the pharmaceutical sector, worldwide, will congregate for business.

     (Photo: http://photos.prnewswire.com/prnh/20141202/10111905-a)

     (Photo: http://photos.prnewswire.com/prnh/20141202/10111905-b)

     (Logo: http://photos.prnewswire.com/prnh/20141117/10111012)

     (Logo: http://photos.prnewswire.com/prnh/20130226/599595-c)

Spread over three days, the event has over 1,000 plus exhibitors from over 100 countries participating. All set to offer opportunities for moving up the global pharma value chain, the event is likely to be attended by over 30,000 delegates from across the globe.

CPhIPharma Insights: India 2015 report

Report highlights: 

• CPhI India report forecasts new MNCs to emerge from India's pharma SMEs and Japan and Africa as key export growth markets
• Indian manufacturers evolving up value chain, concentrating on high-value, low volume work and shifting some R&D programmes to western economies. NCE launch predicted in next few years
• India's biggest companies will see growth in CRAMS services for patented products as trust in regulatory and quality standards increases
  • India to increasingly become a hotbed of clinical trial supply and advanced development work
• Biggest players to grow technology base through overseas acquisitions and partnering with big pharma for R&D
• Expenditures on R&D by thirty of the top pharmaceutical companies in India rose by 19.7%, with investments focused on novel drug delivery systems
  • Some of India's biggest players are actively investing in R&D facilities abroad- Sun, Piramal, Lupin and Cipla
• New chemical entities from India to emerge in the next few years- cutting edge research underway, including innovations in creating an oral dosage form of insulin
• Huge future growth potential in Japan where Indian companies currently have limited presence, but there is predicted to be a rapidly rising use of generics
• In 2015, a significant number Indian companies will enter the African market as growth is predicted at 25% to 30% by volume per year
• Biologics and biosimilars to represent 15% of Indian market value by 2020
• India's API producers have increasingly started to shift towards high value low volume work with complex chemistry and IP challenges

Mr. Joji George, Managing Director, UBM India, said, "Against the backdrop of India constantly seeking to match and surpass western quality standards while maintaining lower manufacturing costs, at UBM, our objective for CPhI 2014 is to help elevate India as the global pharmaceutical destination by showcasing the unique positioning of the Indian pharma market and provide an optimum investment platform amidst its global counterparts."

The India Pharma Awards 2014 winners 

These awards honour innovation and excellence in the Indian pharmaceutical industry, thus creating an industry platform to celebrate the contribution of its key players amongst their Indian and international fraternity. Winners were declared across 9 categories with over 100 companies participating in this year's awards.

Category winners

Operational Excellence - API Dr. Reddy's Laboratories Ltd.

Operational Excellence - Formulation Zydus Cadila Healthcare Ltd.
Excellence in Environment, Health & Safety (EHS) Jubilant Life Sciences Ltd.
Excellence in Packaging Development ACG Worldwide
Excellence in Contract Research Akums Drugs & Pharmaceuticals Ltd.
Excellence in Corporate Social Responsibility 1) Piramal Foundation; 2) Jubilant Life Sciences Ltd.
Emerging Entrepreneur of the Year Ranjeeta Vinil (Saarathi Healthcare Pvt. Ltd.)
Lifetime Achievement Award Mr. Ajit Singh (ACG Worldwide)
Special Jury Award Dr. J N Banerjee

About UBM India 

UBM India is India's leading live media and events company that engages people and enriches businesses. We at UBM India provide the industry with platforms that bring together buyers and sellers from around the world, through a portfolio of exhibitions, content led conferences & seminars, tech media, live events, data services and powerful media brands. UBM India hosts over 20 large scale exhibitions and 40 conferences across the country every year; thereby enabling trade across multiple industry verticals. A UBM Asia Company, UBM India has offices across Mumbai, New Delhi, Bangalore and Chennai. UBM Asia is owned by UBM plc which is listed on the London Stock Exchange. UBM Asia is the leading exhibition organiser in Asia and the biggest commercial organiser in mainland China, India and Malaysia. For further details, please visit www.ubmindia.in

Note: For the PDF of Pharma Insights report please reach out to us directly.

Primary Media Contact: Priya Badshah, [email protected], +91-2261727353, Head - PR, UBM India Pvt Ltd

Secondary Media Contact: Arnab Das, [email protected], +91-9167394888, Group Manager, Madison India